telmisartan has been researched along with Airflow Obstruction, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, SS; Kow, CS | 1 |
| Bolotova, EV; Pavlishchuk, SA; Porkhanov, VA | 1 |
2 other study(ies) available for telmisartan and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Mice; Overweight; Pandemics; Pneumonia, Viral; Pulmonary Disease, Chronic Obstructive; Rats; SARS-CoV-2; Telmisartan | 2020 |
[Efficacy of telmisartan in chronic obstructive lung disease wtih arterial hypertension].
Topics: Aged; Airway Resistance; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Circadian Rhythm; Dose-Response Relationship, Drug; Forced Expiratory Flow Rates; Humans; Hypertension; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Telmisartan; Treatment Outcome | 2005 |